| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-10 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.22 | 3e-10 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.22 | 3e-10 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.22 | 4e-10 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-10 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.21 | 7e-10 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-09 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.23 | 3e-09 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | 0.24 | 3e-09 |
| mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | 0.24 | 3e-09 |